Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Stoke Therapeutics Announces $90M Series B Financing To Advance Novel Oligonucleotide Medicines
Venture Capital

Stoke Therapeutics Announces $90M Series B Financing To Advance Novel Oligonucleotide Medicines

by vcaonline.com posted 11months ago 52 views
Stoke Therapeutics Announces $90 Million Series B Financing to Advance Novel Oligonucleotide Medicines BEDFORD, Mass., October 23, 2018-- Stoke Therapeutics today announced that it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases. The financing round was led by RTW Investments with participation from founding investor Apple Tree Partners. New investors include RA Capital Management, Cormorant Asset Management, Perceptive Advisors, funds managed by Janus Henderson Investors, Redmile Group, Sphera Funds Management, and Alexandria Venture Investments. Roderick Wong, M.D.